Annual USC Update in GI and Liver Diseases: Controversies and Guidelines in 2025

Pre-registration for this event is now closed. To register after Monday, September 9, please visit the on-site registration desk at the Westin Pasadena beginning at 3:00pm on Friday, September 12 and 7:30 am on Saturday, September 13.

Recent breakthroughs in diagnosing and treating gastrointestinal and liver diseases are reshaping patient care. Innovative therapies are transforming the management of IBD, MASLD, Met-ALD, cholestatic liver diseases, and viral hepatitis B/C, while advanced endoscopic and imaging techniques are redefining our approach to pancreaticobiliary diseases, motility disorders, and early luminal neoplasia. Despite these advances, significant knowledge gaps persist.The upcoming conference aims to update community standards of practice by addressing topics such as obesity management, metabolic liver diseases, revised transplant policies, the challenges of alcoholic hepatitis, emerging transplant strategies for cholangiocarcinoma, metastatic colon cancer, and various luminal, upper GI, lower GI, and pancreatic disorders. This event will highlight the latest developments in gastroenterology and hepatology to enhance patient care.

1. Identify advances in third-space endoscopy and complicated biliary cases.
2. Explain the role of supportive techniques in the evaluation of esophageal disorders and how best to evaluate belching, bloating, distention, and other common GI symptoms.
3. Review updates in the medical management of IBD and the management of dysplasia.
4. Outline the newest screening and surveillance approaches for colorectal and pancreatic cancer.
5. Describe the evaluation process for both living liver donors and recipients, encompassing medical, surgical, and patient perspectives, to ensure optimal outcomes and minimize risks associated with living donor liver transplants.
6. Recognize the pathophysiology and clinical implications of acute kidney injury in cirrhosis, including its impact on patient prognosis and management strategies, to improve early detection and treatment approaches in clinical practice.
7. Review the latest advancements in treatments for hepatocellular carcinoma (HCC), including surgical, locoregional, and systemic therapies.
8. Describe methods to optimize the care of the ambulatory patient with cirrhosis and prevent decompensation.
9. Discover insights into recent advances in managing metabolic dysfunction associated with steatohepatitis (MASH), including pharmacological and lifestyle interventions, to address the growing burden of MASH-related liver disease and improve patient outcomes.
10. Examine the latest developments in hepatitis B treatment, including antiviral therapies.

The Keck School of Medicine of the University of Southern California designates this activity for a maximum of 9.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cancellation Policy

Cancellations must be received by the USC Office of CME by fax or email by September 9. 20234 by 12:00 pm PDT for a refund. A $50 cancellation fee will be applied. In the event of course cancellation by conference organizers, all registration fees will be fully refunded. USC will not refund any travel costs incurred.


Accessibility Statement
 
Keck School of Medicine Healthcare System is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the USC Office of CME at [email protected].

To book a room at the Westin Pasadena, please scan the QR code below or visit: https://www.marriott.com/en-us/hotels/laxpw-the-westin-pasadena/rooms/

The Keck School of Medicine Healthcare System School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Naim Alkhouri, MD
Summit Clinical Research
Westlake, OH

Faculty

Grant or research support-89bio|Grant or research support-Akero Therapeutics|Grant or research support-Arbutus Biopharma|Grant or research support-Astra Zeneca|Grant or research support-BioAge|Grant or research support-Boehringer Ingelheim|Grant or research support-Bristol-Myers Squibb|Grant or research support-Corcept Therapeutics|Grant or research support-Galectin Therapeutics|Grant or research support-Genentech|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Hepagene Therapeutics|Grant or research support-Intercept Pharmaceuticals|Grant or research support-Inventiva Pharma|Grant or research support-Ionis Pharmaceuticals|Grant or research support-Ipsen Biopharmaceuticals, Inc.|Grant or research support-Lilly USA|Grant or research support-Madrigal Pharmaceuticals|Grant or research support-Merck, Inc.|Grant or research support-NGM Biopharmaceuticals|Grant or research support-NorthSea Therapeutics|Grant or research support-Novo Nordisk, Inc.|Grant or research support-Perspectum|Grant or research support-Pfizer|Grant or research support-PharmaIN|Grant or research support-Poxel|Grant or research support-Regeneron|Grant or research support-Viking Therapeutics|Grant or research support-Zydus Pharmaceuticals|Speakers Bureau-AbbVie|Speakers Bureau-Astra Zeneca|Speakers Bureau-Echosens|Speakers Bureau-Gilead Sciences, Inc.|Speakers Bureau-Intercept Pharmaceuticals|Speakers Bureau-Ipsen|Speakers Bureau-Madrigal Pharmaceuticals|Speakers Bureau-Perspectum|Paid consultant-89bio|Paid consultant-AbbVie|Paid consultant-Akero|Paid consultant-Boehringer Ingelheim|Paid consultant-Echosens|Paid consultant-Fibronostics|Paid consultant-Gilead Sciences, Inc.|Paid consultant-HistoIndex|Paid consultant-Intercept Pharmaceuticals|Paid consultant-Ipsen Biopharmaceuticals, Inc.|Paid consultant-Madrigal Pharmaceuticals|Paid consultant-NorthSea Therapeutics|Paid consultant-Novo Nordisk, Inc.|Paid consultant-Perspectum|Paid consultant-Pfizer|Paid consultant-Regeneron

Saroja Bangaru, MD
Keck / USC
Los Angeles, CA

Faculty

Nothing to disclose

Danse Bi, MD
USC
Overland Park, KS

Faculty

Nothing to disclose

James Buxbaum, MD
Associate Professor of Medicine
USC
Los Angeles, CA

Faculty

Consulting Fee-Olympus America, Inc.|Consulting Fee-Boston Scientific|Advisor-Panafina and Calcimedica

Cynthia Cherfane, MD
USC
San Marino, CA

Faculty

Nothing to disclose

William D Chey, MD

Faculty

Consulting Fee-Ardelyx|Consulting Fee-Atmo|Consulting Fee-Biomerica|Consulting Fee-Gemelli|Consulting Fee-Phathom|Consulting Fee-Redhill|Consulting Fee-Salix - Valeant|Consulting Fee-Takeda|Grant or research support-Commonwealth Diagnostics|Grant or research support-Salix - Valeant|Stocks or stock options, excluding diversified mutual funds-Coprata|Stocks or stock options, excluding diversified mutual funds-Dieta|Stocks or stock options, excluding diversified mutual funds-Evinature|Stocks or stock options, excluding diversified mutual funds-FoodMarble|Stocks or stock options, excluding diversified mutual funds-Kiwi Bioscience|Stocks or stock options, excluding diversified mutual funds-Modify Health

Lily Dara, MD
Assistant Professor of Medicine
Keck School of Medicine of USC
Los Angeles, CA

Faculty

Grant or research support-Intercept Pharmaceutical|Consulting Fee-Intercept Pharmaceuticals|Consulting Fee-Agios|Consulting Fee-Kezar

Hyosun Han, MD
KSOM-Keck School of Medicine
Los Angeles, CA

Faculty

Nothing to disclose

Brent Hiramoto
KMR-Keck Medical Residents

Faculty

Nothing to disclose

Jeffrey A Kahn, MD
KSOM-Keck School of Medicine
Pasadena, CA

Faculty

Nothing to disclose

Navpreet Kaur, MD
Keck Medicine of USC
Pasadena, CA

Faculty

Nothing to disclose

Brian Kim, MD
Associate Professor of Clinical Medicine
KHS-Keck Health System
Los Angeles, CA

Faculty

Nothing to disclose

Brian Lee, MD, Physician
USC
Los Angeles, CA

Faculty

Nothing to disclose

Florence-Damilola Odufalu, MD
Assistant Professor of Clinical Medicine
Keck Medicine of USC
Los Angeles, CA

Faculty

Nothing to disclose

Nipaporn Pichetshote, MD
USC
Santa Monica, CA

Faculty

Ara Sahakian, MD
physician
USC
La Canada, CA

Faculty

Consulting Fee-Boston Scientific

Anisa Shaker, MD, AGAF
Dr.
Keck School of Medicine of USC
Los Angeles, CA

Faculty

Other: Clinical Trials-Astra Zeneca|Other: Clinical trials-Regeneron

Sarah Sheibani, MD
Assistant Professor of Clinical Medicine
USC
South Pasadena , CA

Faculty

Nothing to disclose

Mohd Raashid Sheikh, MD
University of Southern California
Los Angeles, CA

Faculty

Nothing to disclose

David S Shin, MD
Associate Professor of Clinical Radiology
University of Southern California
La Canada Flintridge, CA

Faculty

Consulting Fee-Stryker (Relationship has ended)

Uzma D Siddiqui, MD
University of Chicago
Chicago, IL

Faculty

Paid consultant-Olympus America, Inc.|Speakers Bureau-Olympus America, Inc.|Grant or research support-Olympus America, Inc.|Advisor-ErgoGI LTD

Edy Soffer, MD
Professor of Clinical Medicine
USC
Los Angeles, CA

Faculty

Nothing to disclose

Harry J Wong, MD, Assistant Professor of Clinical Surgery
Keck Medicine of USC
Los Angeles, CA

Faculty

Consulting Fee-Johnson & Johnson (Relationship has ended)

Liyun Yuan, MD
Assistant Professor of Clinical Medicine
KMR-Keck Medical Residents
Los Angeles, CA

Faculty

Grant or research support-Gilead Sciences, Inc. (Relationship has ended)

Kali Zhou, MD
University of Southern California
Los Angeles, CA

Faculty

Grant or research support-Gilead Sciences, Inc.|Grant or research support-Merck, Inc.